[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:rhabdoid-tumor:glypican-3":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Rhabdoid Tumor","Glypican-3",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[12],"Phase 1","RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[12],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[12],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:27.425045Z"]